PAD4 Inhibitor Therapy Prevents NETs and Improves Neurological Deficits Resulting From Subarachnoid Hemorrhage (P11-13.010)
This study aims to elucidate the role of NETs in SAH pathophysiology and whether their inhibition can act as a therapy for clinical settings. We hypothesize that SAH-induced mice treated with the PAD4 inhibitor, GSK484, will show fewer deficits.
Authors
- Devin W. McBride (ORCID: https://orcid.org/0000-0001-8988-3353)
- Ari Dienel (ORCID: https://orcid.org/0000-0003-4825-5005)
- Sung‐Ha Hong
- Bibek Samal
Institutions
- Rice University (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208899
- Citations
- 1
- Primary Topic
- Intracranial Aneurysms: Treatment and Complications
- Type
- article
- Field-Weighted Citation Impact
- 1.39